A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

BACKGROUND: Serum interleukin (IL)-6 levels correlate with disease outcomes in renal cell carcinoma (RCC) patients. Siltuximab, a chimeric, murine-human mAb against IL-6, was evaluated in a three-part phase I/II study in patients with progressive metastatic RCC. METHODS: In part 1, 11 patients recei...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, J-F, Négrier, S, James, N D, Kocak, I, Hawkins, R, Davis, H, Prabhakar, U, Qin, X, Mulders, P, Berns, B
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967052/
https://www.ncbi.nlm.nih.gov/pubmed/20808314
http://dx.doi.org/10.1038/sj.bjc.6605872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967052/
https://www.ncbi.nlm.nih.gov/pubmed/20808314
http://dx.doi.org/10.1038/sj.bjc.6605872

Ejemplares similares